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Abstract
Objective—Guidelines for prevention of mother-to-child transmission of HIV have developed 
rapidly, yet little is known about how outcomes of HIV-exposed infants have changed over time. 
We describe HIV-exposed infant outcomes in Kinshasa, Democratic Republic of Congo, between 
2007 and 2013.
Design—Cohort study of mother–infant pairs enrolled in family-centered comprehensive HIV 
care.
Methods—Accounting for competing risks, we estimated the cumulative incidences of early 
infant diagnosis, HIV transmission, death, loss to follow-up, and combination antiretroviral 
therapy (cART) initiation for infants enrolled in three periods (2007–2008, 2009–2010, and 2011–
2012).
Results—1707 HIV-exposed infants enrolled at a median age of 2.6 weeks. Among infants 
whose mothers had recently enrolled into HIV care (N = 1411), access to EID by age two months 
increased from 28% (95% confidence limits [CL]: 24,34%) among infants enrolled in 2007-2008 
to 63% (95% CL: 59,68%) among infants enrolled in 2011–2012 (Gray's p-value <0.01). The 18-
month cumulative incidence of HIV declined from 16% (95% CL: 11,22%) for infants enrolled in 
2007–2008 to 11% (95% CL: 8,16%) for infants enrolled in 2011–2012 (Gray's p-value = 0.19). 
The 18-month cumulative incidence of death also declined, from 8% (95% CL: 5,12%) to 3% 
(95% CL: 2,5%) (Gray's p-value = 0.02). LTFU did not improve, with 18-month cumulative 
incidences of 19% (95% CL: 15,23%) for infants enrolled in 2007-2008 and 22% (95% CL: 
18,26%) for infants enrolled in 2011–2012 (Gray's p-value = 0.06). Among HIV-infected infants, 
the 24-month cumulative incidence of cART increased from 61% (95% CL: 43,75%) to 97% 
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(95% CL: 82,100%) (Gray's p-value < 0.01); the median age at cART decreased from 17.9 to 9.3 
months. Outcomes were better for infants whose mothers enrolled before pregnancy.
Conclusions—We observed encouraging improvements, but continued efforts are needed.
Keywords
Democratic Republic of Congo; HIV-exposed infant; mother-infant pair; pediatric HIV; 
prevention of mother-to-child HIV transmission/vertical transmission
Introduction
Globally, an estimated 1.4 million infants are born to HIV-infected pregnant women each 
year [1]. The guidelines for care of HIV-exposed infants have evolved rapidly in recent 
years and ambitious goals for controlling the pediatric HIVepidemic have been set [2,3]. 
Although the incidence of pediatric HIV is declining [1], we still know little about how 
programmatic and clinical outcomes of HIV-exposed infants have changed over time.
A major evolution in the care of HIV-exposed infants occurred with the implementation of 
early infant diagnosis (EID) by virological testing, which was first recommended by the 
WHO in 2007 [4]. Previously, HIV infection in exposed infants could only be confirmed by 
serology at 18 months of age [5,6]. EID is needed to ensure timely combination 
antiretroviral therapy (cART) initiation. Without cART, a third of HIV-infected infants will 
die in the first year of life [7–9].
Since the scale-up of EID, other parts of the prevention of mother-to child HIV transmission 
(PMTCT) landscape have also evolved rapidly (Fig. 1) [4,10–15]. Mounting evidence on the 
importance of breastfeeding for preventing HIV-exposed infant mortality [16–18] led the 
WHO to increase the recommended breastfeeding period from 6 months (2006 
recommendation [11]) to at least 12 months (2010 recommendation [13]). Due to the 
increased risk period for vertical HIV transmission through breastfeeding [19,20], the 
duration and complexity of antiretroviral prophylactic regimens in the 2010 guidelines also 
increased [12]. By 2012, the WHO endorsed lifelong cART for all pregnant women [21].
Evaluating and reporting outcomes in routine care settings is critical to demonstrate the 
scalability of recommended interventions for PMTCT and to assure quality care is being 
provided [22–24]. One study of 561 infants who received care between 2009 and 2012 in the 
Kilimanjaro Region of Tanzania reported 10% mother-to-child HIV transmission [25], 
despite the provision of prophylactic regimens that were expected to reduce vertical 
transmission to below 5% [12]. Another study of 311 mother–infant pairs in Malawi was 
able to reduce transmission to 3%, but 14% of infants died by 24 months of age [26].
These examples from the field highlight that, despite best efforts to implement current 
guidelines, PMTCT programs do not always achieve intended outcomes for HIV-exposed 
infants. Our understanding of the impact that PMTCT programs have had on HIV-exposed 
infant outcomes is incomplete, in part, because guidelines often change before the impacts 
of previous guidelines have been assessed. The goal of this study was to describe how key 
clinical and programmatic outcomes of HIV-exposed infants have changed over time in 
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Kinshasa, Democratic Republic of Congo (DRC), under evolving guidelines for care. 
Beginning with the implementation of HIV-exposed infant care in Kinshasa, we describe 
temporal trends in the timing of EID, HIV transmission, death, and loss to follow-up 
(LTFU), as well as cART initiation among infants identified as HIV-infected. To our 
knowledge, this is the first study to assess if the implementation of new guidelines has 
coincided with improvements in these outcomes for HIV-exposed infants over time.
Methods
Study population
The data for this study come from a family-centered HIV prevention, care, and treatment 
program implemented at two sites (one primary healthcare center and one pediatric hospital) 
in Kinshasa, with technical assistance provided by the University of North Carolina at 
Chapel Hill (UNC-DRC program). The two centralized sites provided comprehensive care 
(including PMTCT) to HIV-positive women identified through routine HIV testing at 90 
maternities and their newborn infants, former patients at 32 tuberculosis clinics, and HIV-
positive children, as well as HIV-positive first-line family members of these individuals. 
Routinely collected data from HIV-exposed infants enrolled between January 2007 and June 
2012 and their mothers were linked to construct a cohort of mother–infant pairs. Mother–
infant linkages were constructed using routinely assigned unique patient codes. Each 
individual's record contained their own patient code, as well as a list of patient codes for 
their family members also receiving care in the UNC-DRC program. Infants enrolled after 
18 months of age and infants not linked to a mother enrolled in the UNCDRC program by 
the time of infant enrollment were excluded.
Routine care and clinic procedures
In accordance with the WHO guidelines, the UNC-DRC protocol included EID by 
virological testing over the entire study period, with initial testing at 6 weeks of age and 
confirmatory virological testing of all positive results performed on a second specimen. 
However, until the end of 2009, HIV RNA assays were the only HIV virological tests 
available at the national laboratory in Kinshasa and stock-outs were frequent. HIV DNA 
PCR testing was implemented in November 2009, by which time the availability of 
virological tests had stabilized. Specimens for DNA PCR testing were collected on dried 
blood spots, which were transported to the national laboratory on a daily basis in vehicles 
provided by the UNC-DRC program. Information on the turnaround time for specimen 
processing was not available. All HIV testing was provided free of charge.
PMTCT prophylactic regimens, cART, and breastfeeding support were provided according 
to current WHO guidelines. Before 2010, the only available PMTCT prophylactic regimen 
for mothers not yet eligible for cART (CD4+ cell count >200) and their infants was single-
dose nevirapine, which was provided according to the 2006 WHO guidelines for programs 
with limited capacity [10]. Mothers were encouraged to exclusively breastfeed for 6 months 
and then wean rapidly [11]. The ‘option A’ strategy was implemented in the DRC following 
the release of the 2010 WHO guidelines [12]. Mothers not yet eligible for cART (CD4+ cell 
count >350) received zidovudine prophylaxis through pregnancy and peripartum nevirapine 
Feinstein et al. Page 3













with a zidovudine–lamivudine ‘tail’ around delivery. Their infants received extended 
nevirapine until 1 week after the cessation of breastfeeding. Mothers were encouraged to 
continue breastfeeding for at least 12 months [13].
Clinic visits for HIV-exposed infants were scheduled to occur every 4 weeks from the first 
visit at 2 weeks of age through 18 weeks of age, and then every 3 months thereafter. Infants 
below 18 months of age were deactivated from care following a negative HIV virological or 
serological test result obtained more than 3 months after the cessation of breastfeeding. 
Infants 18 months of age or older were deactivated from care following the cessation of 
breastfeeding and a negative serological test. HIV-infected infants were eligible to receive 
lifelong care and treatment in the UNC-DRC program. In 2007, infants below 18 months of 
age with a CD4+ cell percentage less than 20, infants 18–24 months of age with a CD4+ cell 
percentage less than 15, and all infants with a WHO clinical stage 3 or 4 were eligible for 
cART [4]. Between 2008 and 2010, infants 12–24 months of age with a CD4+ cell 
percentage less than 20 and all infants less than 12 months of age were eligible to receive 
cART [27]. Starting in 2010, all infants below 24 months of age were eligible for cART 
[14].
Definitions and statistical analysis
Demographics of infants and their mothers at infant enrollment were characterized using 
standard descriptive statistics. Infants were considered underweight or stunted if they had a 
weight-for-age or height-for-age Z-score more than 2 SDs below the median value for a 
given age group and sex. Z-scores were derived from the WHO Child Growth Standards 
[28] using the WHO Anthro software (version 3.2.2, January 2011) and macro for SAS. 
Growth status was based on the first available weight and height values measured within a 
month of enrollment.
Among all HIV-exposed infants, we estimated the 18-month cumulative incidences of 
specimen collection for initial HIV virological testing, confirmed HIV infection, death, and 
LTFU. For HIV-exposed infants with confirmed HIV infection by 18 months of age, we also 
estimated the 24-month cumulative incidence of cART initiation. In the LTFU analysis, 
follow-up time was defined as days from enrollment in care, and infants without a clinic 
visit beyond the enrollment visit were assigned 1 day of follow-up. Infants were considered 
lost to follow-up on their last attended clinic visit date following 3 failed tracking attempts 
after a missed appointment or if more than 6 months passed since they were last seen in the 
clinic. In all other analyses, follow-up time was defined as days from birth. Follow-up 
concluded when the first of the following occurred: the event of interest, a competing event, 
or censoring [29].
Competing risks arise in time-to-event analyses when individuals can experience events that 
preclude them from ever experiencing the event of interest [29]. Our study included multiple 
outcomes of interest, and competing events varied by analysis. Death was treated as a 
competing event in the analyses of specimen collection for HIV virological testing, 
confirmed HIV infection, LTFU, and cART initiation. Graduation from care (i.e. 
deactivation from care after a confirmed negative status or transition to lifelong HIV care if 
positive) was treated as a competing event in the analyses of LTFU, confirmed HIV 
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infection, and death. In the analysis of first specimen collection for HIV virological testing, 
a confirmatory negative diagnosis by serology was also treated as a competing event. LTFU 
and transfer of care to another facility were treated as censoring events. Administrative 
censoring occurred on the date the dataset was closed for final analysis (August 2013) or 
when infants aged out of the risk period of interest (19 months of age in the analyses that 
included all HIV-exposed infants and 25 months of age in the analysis of cART initiation 
among HIV-infected infants).
To assess how infant outcomes changed over time, we compared cumulative incidence 
estimates and 95% confidence limits between infants enrolled in three time periods (2007–
2008, 2009–2010, and 2011–2012). A P-value was obtained for Gray's test for equality of 
the cumulative incidence function [30] using the SAS %CIF macro (version 1.0, March 
2012) [31]. Since all HIV-infected women enrolled in the UNC-DRC program were eligible 
to receive lifelong care, the proportion of infants whose mothers were newly enrolled into 
care during their most recent pregnancy declined over the study period. Because outcomes 
among infants whose mothers were enrolled into care before their current pregnancy may be 
different than those whose mothers were newly enrolled, we stratified comparisons of the 
cumulative incidence functions by maternal enrollment status (enrolled before most recent 
pregnancy or newly enrolled) for all outcomes except infant cART initiation. For this 
outcome, the number of HIV-infected infants whose mothers were previously enrolled was 
too small to allow stratified analyses.
Sensitivity analyses
To assess potential selection bias induced by informative censoring due to LTFU, we 
assessed the extreme bounds [32,33] of the overall 18-month cumulative incidence of HIV. 
The upper bound was estimated assuming all infants who were lost to follow-up instead 
were confirmed HIV-positive on the day they were lost to follow-up. The lower bound was 
estimated assuming all infants who were lost to follow-up were instead confirmed HIV-
negative and ‘graduated’ from care at 18 months of age.
Finally, we wanted to know if implementation of PMTCT services differed between the two 
sites included in the study. To assess for differences, we compared the cumulative incidence 
functions for each of the outcomes of interest stratified by site of care. All analyses were 
conducted in SAS 9.3 (SAS Institute, Inc., Cary, North Carolina, USA).
Ethics statement
Written parental informed consent for the UNC-DRC program was obtained for all infants 
and written informed consent was obtained for all mothers. All research was approved by 
the Ethics Committee of the Kinshasa School of Public Health and the University of North 
Carolina at Chapel Hill Institutional Review Board.
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Among the 1908 HIV-exposed infants enrolled during the study period, 1707 were linked to 
a mother receiving care in the UNC-DRC program and included in the analysis. At 
enrollment, infants were a median of 2.6 weeks of age [interquartile range (IQR) 2.1–6.4] 
and almost all (90.6%) were breastfeeding (Table 1). Three hundred and thirty-six (20.3%) 
infants were underweight and 381 (23.1%) were stunted at enrollment, with little change 
over time. The proportion of infants who failed to receive a PMTCT prophylactic regimen 
declined from 29.7% for infants enrolled in 2007–2008 to 7.7% for infants enrolled in 2011–
2012.
At infant enrollment, mothers were a median of 31.1 years of age (IQR 27.0–34.7) and had 
been enrolled in the UNC-DRC program for a median of 94 days (IQR 23–168) (Table 1). 
Overall, 1331 (78.0%) of mothers received a PMTCT prophylactic regimen or cART during 
their pregnancy and 475 (27.8%) had initiated cART by the time of infant enrollment.
Outcomes of HIV-exposed infants
The 18-month cumulative incidence of having a specimen collected for initial virological 
HIV testing increased over the study period, with 99% [95% confidence limit (CL): 99, 
100%] of the infants enrolled in 2011–2012 having a specimen collected by 18 months of 
age (Table 2). Among infants whose mothers were newly enrolled into care, the cumulative 
incidence of specimen collection by 2 months of age was 28% (95% CL: 24, 34%) for 
infants enrolled in 2007–2008, 49% (95% confidence limits 45, 53%) for infants enrolled in 
2009–2010, and 63% (95% confidence limits 59, 68%) for infants enrolled in 2011–2012.
Among the 1411 infants with newly enrolled mothers, 135 infants were confirmed HIV-
positive, 62 died, and 252 were lost to follow-up over 14 300 person-months of follow-up 
(Table 2). The 18-month cumulative incidence of HIV declined from 16% (95% CL: 11, 
22%) for infants enrolled in 2007–2008 to 11% (95% CL: 8, 16%) for infants enrolled in 
2011–2012 and death declined from 8% (95% CL: 5, 12%) to 3% (95% CL: 2, 5%) (Table 2 
and Fig. 2). The 18-month cumulative incidence of LTFU did not improve over calendar 
time, with 18-month cumulative incidences ranging from 16% (95% CL: 13, 19%) to 22% 
(95% CL: 18, 26%) (Fig. 3).
Among the 296 infants whose mothers enrolled before their current pregnancy, 7 infants 
were confirmed HIV-positive, 11 died, and 24 were lost to follow-up over 3949 person-
months of follow-up (Table 2). The 18-month cumulative incidence of HIV declined from 
5% (95% CL: 0, 21%) for infants enrolled in 2007–2008 to 1% (95% CL: 0, 3%) for infants 
enrolled in 2011–2012 (Table 2 and Fig. 2). Death also declined over calendar time, with 
18-month cumulative incidences of 5% (95% CL: 0, 21%) for infants enrolled in 2007–2008 
and 3% (95% CL: 1, 7%) for infants enrolled in 2011–2012. LTFU increased from 0% (95% 
CL: 0, 0%) to 9% (95% CL: 5, 14%).
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Combination antiretroviral therapy initiation among HIV-infected infants
Among the 142 infants with confirmed HIV infection by 18 months of age, the median age 
at enrollment into care was 6.4 weeks (IQR: 2.3–32.0 weeks) and the median age at 
specimen collection for initial virological HIV testing was 17.3 weeks (IQR: 7.3–46.0 
weeks). The 24-month cumulative incidence of starting cART increased over time, from 
61% (95% CL: 43, 75%) for infants enrolled in 2007–2008 to 97% (95% CL: 82, 100%) for 
infants enrolled in 2011–2012 (Table 2 and Fig. 2). The median time between enrollment 
and cART initiation declined from 12.1 to 3.8 months, and the median age at cART 
initiation decreased from 17.9 to 9.3 months.
Sensitivity analyses
Our sensitivity analysis suggested that our estimates of the 18-month cumulative incidence 
of HIV may be susceptible to bias due to LTFU. Among all infants, the 18-month 
cumulative incidence of HIV was 11% (95% CL: 9, 13%). Assuming all infants who were 
lost to follow-up were instead confirmed HIV-positive, the estimate was 26% (95% CL: 24, 
28%). Assuming all infants who were lost to follow-up were HIV-negative and ‘graduated’ 
from care at 18 months of age, the estimate was 9% (95% CL: 8, 11%).
There appeared to be some differences in infant outcomes between the two sites included in 
the analysis. The only differences that were statistically significant (i.e. Gray's P-value < 
0.05) were specimen collection for HIV virological testing and confirmed HIV infection. At 
the pediatric hospital, the 18-month cumulative incidence of specimen collection was 82% 
(95% confidence limits 78, 85%) and the 18-month cumulative incidence of HIV was 12% 
(95% CI: 8, 16%). At the primary care center, the 18-month cumulative incidence of 
specimen collection was 94% (95% CI: 93, 96%) and the 18-month cumulative incidence of 
confirmed HIV was 11% (95% CI: 9, 14%).
Discussion
Our program's experience in Kinshasa shows that improvements over time can be achieved 
in a routine care setting under evolving guidelines for care. Among infants whose mothers 
were newly enrolled during their most recent pregnancy, we observed declines in both 
vertical HIV transmission and infant death. The 18-month cumulative incidence of HIV was 
30% lower among infants enrolled in 2011–2012 than among infants enrolled in 2007–2008. 
The 18-month cumulative incidence of death declined by 60%. Among HIV-infected 
infants, we also observed an increase in the proportion initiating cART, with over 95% of 
infants enrolled in 2011–2012 initiating cART by 24 months of age.
Despite these achievements, our results, also reveal areas for improvement. Among infants 
in the 2011–2012 cohort, whose mothers were newly enrolled, the proportion with 
confirmed HIV infection by 18 months of age was still over 10% and our sensitivity 
analyses suggested that this may be an underestimate if those who were lost to follow-up 
were at a higher risk of HIV than those who were retained in care. Effective interventions 
can reduce transmission to below 5% in breastfeeding populations [34]. In our study, about 
20% of mothers had not received a PMTCT prophylactic regimen or cART by delivery. 
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Furthermore, most HIV-infected infants enrolled in 2011–2012 still did not have their 
positive status confirmed until after 9 months of age, and 21% of all infants died or were lost 
to follow-up before their HIV status could be determined. The proportion of infants 
presenting to care in poor health also remained high throughout the study period, with about 
20% under-weight and 20% stunted overall.
Early infant diagnosis by virological testing did not become consistently available in 
Kinshasa until about halfway through the study period. An important limitation to our study 
is that the UNC-DRC program did not routinely collect information on how much time 
passed between specimen collection for virological testing and when results became 
available for clinical decision-making. Although the 18-month cumulative incidence of 
specimen collection increased to almost 100% over the study period, many infants failed to 
have a specimen collected by the 4–6-week target [15]. By 2 months of age, about 40% of 
infants with newly enrolled mothers still had not had a specimen collected. This figure 
leaves ample room for improvement, but is substantially higher than that reported for the 
country as a whole; a recent Joint United Nations Programme on HIV and AIDS report 
estimated that only 3% of HIV-exposed infants in the DRC received a virological test for 
HIV by 2 months of age [1].
Diagnosing HIV in infected infants as early as possible is crucial because up to a third may 
die in the first year of life without cART [7–9,14]. We observed that the median months 
from enrollment in care to cART initiation decreased from 12 months among infants 
enrolled in 2007–2008 to 4–5 months for infants enrolled in later periods, likely due to the 
increased availability of EID. However, half of HIV-infected infants enrolled in 2011– 2012 
had not initiated cART by 9 months of age and over a quarter had not initiated cART by 12 
months of age. There are likely several reasons why infants continue to experience delayed 
cART initiation despite the availability of EID. In our setting, one reason may have been 
that HIV-infected infants enrolled in care later than the population of all HIV-exposed 
infants. Although median age at enrollment was only 3 weeks more, over a quarter of HIV-
infected infants enrolled in care after 32 weeks of age.
The number of studies describing obstacles to EID has increased [35–38], but a recent meta-
analysis found that only one study traced HIV-infected infants from enrollment in PMTCT 
care to cART initiation [39]. The study, which included 202 HIV-infected infants in Malawi, 
observed that although the delay in cART initiation declined over time, the overall 
proportion of HIV-infected infants initiating cART did not improve [38]. It is crucial that 
PMTCT programs routinely record individual-level information at each step of the test-and-
treat cascade and future research should assess where and why bottlenecks to the provision 
of early cART exist. Initiating the EID process at birth, particularly for high-risk infants, 
may also decrease delays in cART initiation [40].
Research has shown that infant nevirapine, a component of the PMTCT options A, B, and B
+, can select non-nucleoside reverse transcriptase inhibitor mutations in the majority of 
infants who become infected with HIV despite prophylaxis [41]. Diagnosing HIV in infected 
infants early reduces exposure to nevirapine prophylaxis and thus the potential for HIV drug 
resistance. Given existing challenges to EID implementation in many settings, future studies 
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should assess how HIV drug resistance and other treatment outcomes of HIV-infected 
infants change with the implementation of new PMTCT guidelines.
Unlike other outcomes assessed in this study, LTFU did not improve over calendar time and 
even appeared to increase among infants whose mothers enrolled in HIV care before their 
current pregnancy (although the increase was not statistically significant). The new 
consolidated WHO guidelines [15], which recommend interventions to improve program 
retention, may reduce obstacles to continued engagement in care. The UNC-DRC program 
increased its efforts to track patients who missed appointments over the study period, but it 
does not appear that these efforts led to a reduction in the proportion of infants who were 
lost to follow-up. Research suggests that infants are less likely to be retained in care if their 
caregivers perceive them as healthy and more likely to be retained in care if they are 
identified as HIV-infected [42,43]. Thus, it is possible that the implementation of EID and 
the communication of initial negative test results, as well as the implementation of more 
effective prophylactic regimens, also affected the proportion of infants who were lost to 
follow-up. In addition, increased tracking efforts likely led to infants being classified as lost 
to follow-up more quickly in later periods than in earlier periods, potentially leading to some 
degree of bias with regards to ascertaining infant mortality or HIV infection status.
Most of the LTFU we observed occurred in the first 6 months after infants enrolled, with 
about 5% never returning for a follow-up visit. A recent meta-analysis that assessed the 
magnitude of LTFU of HIV-exposed infants along the PMTCT cascade also reported high 
LTFU early in follow-up, with 4–75% LTFU by 3 months of age [44]. Interventions to 
improve retention should be implemented at the first contact. Point-of-care services may 
also improve retention [45,46].
We observed that infants whose mothers were newly enrolled into care generally had worse 
outcomes than infants whose mothers who were already enrolled in care when they became 
pregnant. Retaining mothers in care beyond the pregnancy and postnatal period may 
improve outcomes among subsequent HIV-exposed infants. As cART has been associated 
with reduced LTFU among HIV-infected adults [47,48], increasing access to lifelong cART 
for pregnant women could facilitate retaining mothers in care.
It is important to note that the infants included in this study and their mothers received 
PMTCTand cART services at centralized sites providing comprehensive HIV care. PMTCT 
services may not be delivered as effectively at sites in Kinshasa providing decentralized 
services [49]. The sites in this study provided routine care services, were integrated into the 
existing healthcare system, and were supervised by the government. In addition, they served 
a patient population that was likely representative of other patient populations in Kinshasa. 
However, technical assistance of the caliber provided by the UNC-DRC program is not 
routinely available in most settings. Quality assurance was an explicit program priority and 
may have contributed to the improvements we observed [50].
We believe our program's results are more or less representative of what can be achieved by 
other programs that provide technical assistance to clinics delivering PMTCT services. 
However, specific implementation challenges will likely vary between settings. Even within 
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our own program, we observed differences in some infant outcomes that suggested there 
were differences between the two sites in how effectively EID and other PMTCT services 
were implemented. It is important that programs assess outcomes disaggregated by clinic in 
order to assure quality improvement activities are appropriately targeted, even if aggregated 
program results are ultimately disseminated.
Another major evolution in the care of HIV-exposed infants is occurring now with the 
worldwide scale-up of the 2013 WHO guidelines that endorse lifelong cART for all 
pregnant women (option B+) [15]. Although PMTCT programs should continue to adopt 
new guidelines as they become available, they should also pay close attention to the quality 
of care provided and routinely monitor intended program outcomes. We observed 
encouraging improvements in the outcomes of HIV-exposed infants in Kinshasa, but there 
remains abundant progress to be made. Modifiable barriers to delivering interventions in 
routine care settings need to be identified and addressed, and we should continue to evaluate 
our progress over time.
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Fig. 1. Evolution of WHO guidelines for prevention of mother-to-child transmission of HIV
3TC, lamivudine; AZT, zidovudine; cART, combination antiretroviral therapy; NVP, 
nevirapine; PMTCT, prevention of mother-to-child HIV transmission; sdNVP, single dose 
of nevirapine.
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Fig. 2. Eighteen-month cumulative incidence functions of confirmed HIV infection, death, and 
loss to follow-up among HIV-exposed infants in Kinshasa, Democratic Republic of Congo
Cumulative incidence functions are plotted by calendar period at infant enrollment into care 
and enrollment status of the mother (newly enrolled during pregnancy or previously 
enrolled). P-values are for Gray's test for equality of the cumulative incidence functions. 
LTFU, loss to follow-up.
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Fig. 3. Twenty-four-month cumulative incidence function of combination antiretroviral therapy 
initiation among HIV-infected infants in Kinshasa, Democratic Republic of Congo
Cumulative incidence functions are plotted by calendar period at infant enrollment into care. 
The P-value is for Gray's test for equality of the cumulative incidence functions.
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Table 1
Characteristics of HIV-exposed infants and their mothers at infant enrollment into care, 
by calendar period, Kinshasa, Democratic Republic of Congo
Year of infant enrollment into care
2007–2012 (N = 1707) 2007–2008 (N = 335) 2009–2010 (N = 730) 2011–2012 (N = 642)
Infants
 Median age in weeks (IQR) 2.6 (2.1–6.4) 2.9 (2.1–9.7) 2.4 (2.1–6.0) 2.6 (2.1–6.0)
 Sex [N (%)]
  Female 872 (51.1) 175 (52.2) 375 (51.4) 322 (50.2)
  Male 835 (48.9) 160 (47.8) 355 (48.6) 320 (49.8)
 PMTCT regimen [N (%)]
  No 243 (16.7) 76 (29.7) 119 (20.9) 48 (7.7)
  Yes 1210 (83.3) 180 (70.3) 451 (79.1) 579 (92.3)
 Breastfeeding [N (%)]
  No 123 (9.4) 29 (13.1) 58 (13.1) 36 (5.6)
  Yes 1182 (90.6) 193 (86.9) 384 (86.9) 605 (94.4)
 Cotrimoxazole prophylaxis [N (%)]
  No 86 (5.0) 19 (5.7) 28 (3.8) 39 (6.1)
  Yes 1621 (95.0) 316 (94.3) 702 (96.2) 603 (93.9)
 Underweighta [N (%)]
  No 1317 (79.7) 248 (79.2) 564 (79.1) 505 (80.5)
  Yes 336 (20.3) 65 (20.8) 149 (20.9) 122 (19.5)
 Stuntedb [N (%)]
  No 1268 (76.9) 233 (75.6) 545 (76.5) 490 (77.9)
  Yes 381 (23.1) 75 (24.4) 167 (23.5) 139 (22.1)
Mothers
 Median age in years (IQR) 31 (27–35) 31 (28–35) 31 (27–34) 31 (27–35)
 Median days enrolled (IQR) 94 (23–168) 75 (32–129) 89 (0–154) 117 (23–531)
 Newly enrolled during most recent pregnancy [N (%)]
  No 296 (17.3) 20 (6.0) 94 (12.9) 182 (28.3)
  Yes 1411 (82.7) 315 (94.0) 636 (87.1) 460 (71.7)
 PMTCT regimen [N (%)]c
  No 376 (22.0) 76 (22.7) 176 (24.1) 124 (19.3)
  Yes 1331 (78.0) 259 (77.3) 554 (75.9) 518 (80.7)
 cART initiated [N (%)]d
  No 1232 (72.2) 279 (83.3) 563 (77.1) 390 (60.7)
  Yes 475 (27.8) 56 (16.7) 167 (22.9) 252 (39.3)
cART, combination antiretroviral therapy; IQR, interquartile range; PMTCT, prevention of mother-to-child HIV transmission. Covariate totals may 
not add up to the column totals due to missing data.
a
Underweight defined as weight-for-age Z-score −2 or less.
b
Stunted defined as height-for-age Z-score −2 or less.
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c
Includes any maternal regimen (described in more detail in the methods section), including maternal cART if initiated before delivery.
d
Includes maternal cART initiated before infant enrollment.
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